These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2475521)

  • 21. Antigen presentation in an HLA-DR-restricted fashion by B-cell chronic lymphocytic leukemia cells.
    Yasukawa M; Shiroguchi T; Inatsuki A; Kobayashi Y
    Blood; 1988 Jul; 72(1):102-8. PubMed ID: 2455565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
    Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
    Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of natural killer-like activity in mixed lymphocyte-tumor cell cultures. I. Role of HLA-DR antigens as stimulatory molecules.
    Matera L; Francis MK; Herlyn M; Trucco M; Santoli D
    Nat Immun Cell Growth Regul; 1985; 4(2):90-102. PubMed ID: 3160934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "NK-like" T cytotoxicity against B lymphocytes in a hypogammaglobulinemic patient.
    Kaplanski G; Seidel-Farnarier C; Durand JM; Harlé JR; Horchowski N; Fossat C; Bongrand P; Kaplanski S
    Immunol Invest; 1992 Dec; 21(7):601-12. PubMed ID: 1487318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrinsic Resistance of Chronic Lymphocytic Leukemia Cells to NK Cell-Mediated Lysis Can Be Overcome
    Wurzer H; Filali L; Hoffmann C; Krecke M; Biolato AM; Mastio J; De Wilde S; François JH; Largeot A; Berchem G; Paggetti J; Moussay E; Thomas C
    Front Immunol; 2021; 12():619069. PubMed ID: 34108958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy.
    Laprevotte E; Voisin G; Ysebaert L; Klein C; Daugrois C; Laurent G; Fournie JJ; Quillet-Mary A
    J Immunol; 2013 Oct; 191(7):3634-40. PubMed ID: 23997218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids.
    Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
    Clin Exp Immunol; 2003 Jan; 131(1):82-9. PubMed ID: 12519390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppression of T-cell response in autologous mixed lymphocyte-tumor culture by large granular lymphocytes.
    Uchida A; Klein E
    J Natl Cancer Inst; 1986 Mar; 76(3):389-98. PubMed ID: 2419621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of B lymphocytes by natural killer cells. Role of IFN-gamma.
    Michael A; Hackett JJ; Bennett M; Kumar V; Yuan D
    J Immunol; 1989 Feb; 142(4):1095-101. PubMed ID: 2492576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lysis of fresh human tumor cells by autologous large granular lymphocytes and T-lymphocytes: two distinct killing activities induced by coculture with autologous tumor.
    Uchida A; Moore M
    J Natl Cancer Inst; 1984 Dec; 73(6):1285-92. PubMed ID: 6239944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of interleukin 3 but not interleukin 2 or interferon production in the syngeneic mixed lymphocyte reaction.
    Suzuki R; Suzuki S; Igarashi M; Kumagai K
    J Immunol; 1986 Sep; 137(5):1564-72. PubMed ID: 2427574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function.
    Burton JD; Weitz CH; Kay NE
    Am J Hematol; 1989 Feb; 30(2):61-7. PubMed ID: 2783634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha.
    Katrinakis G; Kyriakou D; Papadaki H; Kalokyri I; Markidou F; Eliopoulos GD
    Acta Haematol; 1996; 96(1):16-23. PubMed ID: 8677756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Generation of non MHC restricted killing in non-cytotoxic T-lymphocytes from leukaemia patients.
    Matera L; Cardoso E; Caudana L; Moore M
    Br J Haematol; 1987 Feb; 65(2):151-7. PubMed ID: 2950919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro function of a T-cell chronic lymphocytic leukemia with suppressor cell phenotype.
    Crosier PS
    Aust N Z J Med; 1986 Jun; 16(3):389-92. PubMed ID: 2946284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.
    Reiners KS; Topolar D; Henke A; Simhadri VR; Kessler J; Sauer M; Bessler M; Hansen HP; Tawadros S; Herling M; Krönke M; Hallek M; Pogge von Strandmann E
    Blood; 2013 May; 121(18):3658-65. PubMed ID: 23509156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL.
    Alvarez de Mon M; Casas J; Laguna R; Toribio ML; de Landázuri MO; Durántez A
    Blood; 1986 Jan; 67(1):228-32. PubMed ID: 3079643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell chronic lymphocytic leukemia-derived dendritic cells stimulate allogeneic T-cell response and express chemokines involved in T-cell migration.
    Łuczyński W; Stasiak-Barmuta A; Piszcz J; Iłendo E; Kowalczuk O; Krawczuk-Rybak M
    Neoplasma; 2007; 54(6):527-35. PubMed ID: 17949237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.
    Veuillen C; Aurran-Schleinitz T; Castellano R; Rey J; Mallet F; Orlanducci F; Pouyet L; Just-Landi S; Coso D; Ivanov V; Carcopino X; Bouabdallah R; Collette Y; Fauriat C; Olive D
    J Clin Immunol; 2012 Jun; 32(3):632-46. PubMed ID: 22318393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.